UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dorsal Striatal Circuits for Habits, Compulsions and Addictions

Frontiers in systems neuroscience, 2019-07, Vol.13, p.28-28

2019

Volltextzugriff (PDF)

Autoinhibition of a Neuronal Kinesin UNC-104/KIF1A Regulates the Size and Density of Synapses

Cell reports (Cambridge), 2016-08, Vol.16 (8), p.2129-2141

2016

Volltextzugriff (PDF)

Rapid Assembly of Presynaptic Materials behind the Growth Cone in Dopaminergic Neurons Is Mediated by Precise Regulation of Axonal Transport

Cell reports (Cambridge), 2018-09, Vol.24 (10), p.2709-2722

2018

Volltextzugriff (PDF)

EphB-Mediated Degradation of the RhoA GEF Ephexin5 Relieves a Developmental Brake on Excitatory Synapse Formation

Cell, 2010-10, Vol.143 (3), p.442-455

2010

Volltextzugriff (PDF)

The Angelman Syndrome Protein Ube3A Regulates Synapse Development by Ubiquitinating Arc

Cell, 2010-03, Vol.140 (5), p.704-716

2010

Volltextzugriff (PDF)

Lamentations through the centuries

1st edition, 2013

Volltextzugriff (PDF)

The Angelman Syndrome-associated ubiquitin ligase Ube3A regulates synapse development by ubiquitinating Arc

Cell, 2010-03, Vol.140 (5), p.704-716

2010

Volltextzugriff (PDF)

Removatron International Counsel Responds to FTC Decision

Business Wire, 1988, p.1

Lipton, David M

1988

Volltextzugriff (PDF)

Case Studies: Organic Vapor Emissions from Wall-to-Wall Carpets as a Source of Indoor Air Pollution

Applied occupational and environmental hygiene, 1996-05, Vol.11 (5), p.436-439

1996

Volltextzugriff (PDF)

Case Studies Respirable Crystalline Silica Dust Exposure during Abrasive Blast Cleaning of Bridge Deck Surfaces

Applied occupational and environmental hygiene, 1996-02, Vol.11 (2), p.81-83

1996

Volltextzugriff (PDF)

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

Lancet neurology, 2014-11, Vol.13 (11), p.1100-1107

2014

Volltextzugriff (PDF)

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

The New England journal of medicine, 2019-07, Vol.381 (2), p.142-149

2019

Volltextzugriff (PDF)

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

Lancet neurology, 2015-11, Vol.14 (11), p.1081-1090

2015

Volltextzugriff (PDF)

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

Cephalalgia, 2010-07, Vol.30 (7), p.804-814

2010

Volltextzugriff (PDF)

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2021-01, Vol.397 (10268), p.51-60

2021

Volltextzugriff (PDF)

Atogepant for the Preventive Treatment of Migraine

The New England journal of medicine, 2021-08, Vol.385 (8), p.695-706

2021

Volltextzugriff (PDF)

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2019-11, Vol.322 (19), p.1887

2019

Volltextzugriff (PDF)

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

Cephalalgia, 2010-07, Vol.30 (7), p.793-803

2010

Volltextzugriff (PDF)

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2

Neurology, 2020-03, Vol.94 (13), p.e1365

2020

Volltextzugriff (PDF)

Ubrogepant for the Treatment of Migraine

The New England journal of medicine, 2019-12, Vol.381 (23), p.2230-2241

2019

Volltextzugriff (PDF)

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

The Lancet (British edition), 2019-08, Vol.394 (10200), p.737-745

2019

Volltextzugriff (PDF)

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy

Neurology, 2020-05, Vol.94 (20)

2020

Volltextzugriff (PDF)

Identification and Characterization of MtoA: A Decaheme c-Type Cytochrome of the Neutrophilic Fe(II)-Oxidizing Bacterium Sideroxydans lithotrophicus ES-1

Frontiers in microbiology, 2012-01, Vol.3, p.37-37

2012

Volltextzugriff (PDF)

Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study

Journal of headache and pain, 2020-03, Vol.21 (1), p.23-23, Article 23

2020

Volltextzugriff (PDF)

Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation

Clinical infectious diseases, 2004-11, Vol.39 (10), p.1407-1416

2004

Volltextzugriff (PDF)

1 – 25 von 480

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(441)
Mit Volltextzugriff
(399)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(479)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Dorsal Striatal Circuits for Habits, Compulsions and Addictions

Autoinhibition of a Neuronal Kinesin UNC-104/KIF1A Regulates the Size and Density of Synapses

Rapid Assembly of Presynaptic Materials behind the Growth Cone in Dopaminergic Neurons Is Mediated by Precise Regulation of Axonal Transport

EphB-Mediated Degradation of the RhoA GEF Ephexin5 Relieves a Developmental Brake on Excitatory Synapse Formation

The Angelman Syndrome Protein Ube3A Regulates Synapse Development by Ubiquitinating Arc

Lamentations through the centuries

The Angelman Syndrome-associated ubiquitin ligase Ube3A regulates synapse development by ubiquitinating Arc

Removatron International Counsel Responds to FTC Decision

Case Studies: Organic Vapor Emissions from Wall-to-Wall Carpets as a Source of Indoor Air Pollution

Case Studies Respirable Crystalline Silica Dust Exposure during Abrasive Blast Cleaning of Bridge Deck Surfaces

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

Atogepant for the Preventive Treatment of Migraine

Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2

Ubrogepant for the Treatment of Migraine

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy

Identification and Characterization of MtoA: A Decaheme c-Type Cytochrome of the Neutrophilic Fe(II)-Oxidizing Bacterium Sideroxydans lithotrophicus ES-1

Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study

Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation

Suchergebnisse filtern